Another DNMT inhibitor, decitabine (DAC), is widely prescribed for treating acute myeloid leukemia (AML) and is recommended for patients with high-risk myelodysplastic syndrome (MDS). Here, DNMT1 is linked to myelodysplastic syndrome.